Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.
Body Mass Index (BMI) of approximately 18 to 30 kg/m2. Total body weight >50 kg (110 lbs).
Pregnant or nursing females. females of childbearing potential. Evidence or history of
clinically significant hematological, renal (including kidney stones), endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic
disease (including drug allergies, but excluding untreated, asymptomatic, seasonal
allergies at time of dosing) or clinical findings at screening.
Treatment with an investigational drug within 30 days (or determined by the local
requirement, whichever is longer) or 5 half-lives preceding the first dose of study